RT Journal Article
SR Electronic
T1 Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.22.20074351
DO 10.1101/2020.04.22.20074351
A1 Lista, Maria Jose
A1 Matos, Pedro M.
A1 Maguire, Thomas J. A.
A1 Poulton, Kate
A1 Ortiz-Zapater, Elena
A1 Page, Robert
A1 Sertkaya, Helin
A1 Ortega-Prieto, Ana M.
A1 O’Byrne, Aoife M.
A1 Bouton, Clement
A1 Dickenson, Ruth E
A1 Ficarelli, Mattia
A1 Jimenez-Guardeño, Jose M.
A1 Howard, Mark
A1 Betancor, Gilberto
A1 Galao, Rui Pedro
A1 Pickering, Suzanne
A1 Signell, Adrian W
A1 Wilson, Harry
A1 Cliff, Penelope
A1 Tan Kia Ik, Mark
A1 Patel, Amita
A1 MacMahon, Eithne
A1 Cunningham, Emma
A1 Doores, Katie
A1 Agromayor, Monica
A1 Martin-Serrano, Juan
A1 Perucha, Esperanza
A1 Mischo, Hannah E.
A1 Shankar-Hari, Manu
A1 Batra, Rahul
A1 Edgeworth, Jonathan
A1 Zuckerman, Mark
A1 Malim, Michael H.
A1 Neil, Stuart
A1 Martinez-Nunez, Rocio Teresa
YR 2021
UL http://medrxiv.org/content/early/2021/04/11/2020.04.22.20074351.abstract
AB There is a worldwide need for reagents to perform SARS-CoV-2 detection. Some laboratories have implemented kit-free protocols, but many others do not have the capacity to develop these and/or perform manual processing. We provide multiple workflows for SARS-CoV-2 nucleic acid detection in clinical samples by comparing several commercially available RNA extraction methods: QIAamp Viral RNA Mini Kit (QIAgen), RNAdvance Blood/Viral (Beckman) and Mag-Bind Viral DNA/RNA 96 Kit (Omega Bio-tek). We also compared One-step RT-qPCR reagents: TaqMan Fast Virus 1-Step Master Mix (FastVirus, ThermoFisher Scientific), qPCRBIO Probe 1-Step Go Lo-ROX (PCR Biosystems) and Luna® Universal Probe One-Step RT-qPCR Kit (Luna, NEB). We used primer-probes that detect viral N (EUA CDC) and RdRP (PHE guidelines). All RNA extraction methods provided similar results. FastVirus and Luna proved most sensitive. N detection was more reliable than that of RdRP, particularly in samples with low viral titres. Importantly, we demonstrate that treatment of nasopharyngeal swabs with 70 degrees for 10 or 30 min, or 90 degrees for 10 or 30 min (both original variant and B 1.1.7) inactivates SARS-CoV-2 employing plaque assays, and that it has minimal impact on the sensitivity of the qPCR in clinical samples. These findings make SARS-CoV-2 testing portable to settings that do not have CL-3 facilities. In summary, we provide several testing pipelines that can be easily implemented in other laboratories and have made all our protocols and SOPs freely available at https://osf.io/uebvj/.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://osf.io/uebvj/ Funding StatementThis work was funded by; Kings Together Rapid COVID-19 Call awards to RTM-N, MHM, KD, SN, JE and MS-H, MRC Discovery Award MC/PC/15068 to SN, KD and MHM, a Huo Family Foundation Award to MHM, KD, RTM-N, SN, JE and MS-H, MRC Programme Grant MR/S023747/1 to MHM, Wellcome Trust Investigator Award 106223/Z/14/Z to MHM, NIAID Awards U54AI150472 and R01AI076119 to MHM. A.S., M.F. and R.E.D. were supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1); E. O-Z was supported by MR/S009191/1 to Parsons M and Santis G; M.F. was supported by the MRC (MR/R50225X/1); H.S was supported by the BBSRC (BB/P504609/1); R.P. was supported by the by the (NIHR) Biomedical Research Centre based at Guys and St Thomas NHS Foundation Trust and Kings College London; T.J.A.M. was supported by Asthma UK at the Asthma UK Centre in Allergic Mechanisms of Asthma; P.M., S. P. and H.W. were supported by WT098049AIA to Neil S. and Swanson C.; M.J.L.B and C.B. were supported by MRC (MR/S000844/1) to Neil S. and Swanson C. This UK funded award is part of the EDCTP2 programme supported by the European Union; K.P. was funded by KHP Challenge Fund to R.T.M-N; M.H. was funded by RP_007_20190305 from Kidney research UK; H.M. was funded by the Wellcome Trust and Royal Society Sir Henry Dale Fellowship 218537/Z/19/Z.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Guy's and St Thomas' NHS Foundation Trust King's College HospitalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data files are available to anyone that requires them. Our protocols are also published at https://osf.io/uebvj/ https://osf.io/uebvj/